Want to see IN:LAURUSLABS full AI Analyst Report?

Laurus Labs Ltd. (LAURUSLABS) Price & Analysis

11 Followers

LAURUSLABS Stock Chart & Stats

₹1602.30

₹112.20(7.01%)

At close: Jul 27 4:00 PM EDT

₹1602.30

₹112.20(7.01%)

Day’s Range― - ―

52-Week Range₹901.85 - ₹2,087.00

Previous CloseN/A

Volume7.99M

Average Volume (3M)84.97K

Market Cap

₹1.11T

Enterprise Value₹560.82B

Total Cash (Recent Filing)₹1.14B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)99.4

Beta0.94

Next Earnings

Oct 29, 2026

EPS Estimate

6.67

Next Dividend Ex-DateN/A

Dividend Yield0.1%

Share Statistics

EPS (TTM)20.25

Shares Outstanding540,312,200

10 Day Avg. Volume98,411

30 Day Avg. Volume84,968

Financial Highlights & Ratios

PEG Ratio0.41

Price to Book (P/B)10.11

Price to Sales (P/S)7.86

P/FCF Ratio137.56

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹1,700.00

Price Target Upside6.10% Upside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)25.13

Revenue Forecast (FY)₹83.45B

Bulls Say, Bears Say

Bulls Say

Profitability RecoveryFY2026’s revenue recovery and sharp net-margin improvement indicate that demand and profitability have regained traction after weaker periods. If maintained, the rebound can strengthen internal funding and support investment, although durability depends on converting sales into cash and preserving margins.

Improving LeverageLower debt-to-equity and a rising equity base improve Laurus Labs’ financial resilience and reduce balance-sheet pressure. Manageable leverage gives the company greater capacity to fund manufacturing scale and development while making it less vulnerable to earnings volatility than in prior periods.

Diversified Pharmaceutical PlatformOperating across APIs, finished formulations, and CDMO services gives Laurus Labs multiple routes to capture pharmaceutical value and customer spending. This integrated platform can support repeat business, broaden market access, and reduce reliance on a single product category or revenue stream over time.

Bears Say

Weak Free Cash FlowPersistently weak free cash flow means reported earnings are not yet translating efficiently into discretionary cash. Heavy capital spending or working-capital absorption can constrain debt reduction, reinvestment, and shareholder returns, leaving less financial flexibility if operating conditions weaken.

Gross Margin CompressionThe sharp decline in gross margin raises concern that the recent profit recovery may not fully reflect durable pricing power. Continued cost, pricing, or product-mix pressure could limit operating leverage and require stronger volume growth to sustain earnings despite the improved net margin.

Choppy Earnings ProfileThe uneven revenue trajectory and EBITDA margins below earlier peaks indicate that earnings power has improved but is not fully stabilized. Such variability can make capacity planning and capital allocation less predictable, while leaving future results dependent on sustained demand and margin normalization.

Laurus Labs Ltd. News

Laurus Labs schedules Q2 and H1 FY27 earnings call for October 29

Laurus Labs Ltd. ( ($IN:LAURUSLABS) ) has shared an announcement. Laurus Labs Ltd. has scheduled an earnings conference...

10d ago

Laurus Labs Raises Investment in Renewable Energy Associate Without Changing Stake

The latest update is out from Laurus Labs Ltd. ( ($IN:LAURUSLABS) ). Laurus Labs Limited has increased its...

17d ago

Laurus Labs Files Q1 FY27 Earnings Call Transcript with Exchanges

Laurus Labs Ltd. ( ($IN:LAURUSLABS) ) has provided an update. Laurus Labs Ltd. has notified stock exchanges that...

3M ago

Laurus Labs’ Composite Scheme of Arrangement Moves to NCLT Hearing in September

Laurus Labs Ltd. ( ($IN:LAURUSLABS) ) just unveiled an announcement. Laurus Labs Limited, a diversified pharmaceutical manufacturer with...

3M ago

Laurus Labs Posts Audio of Q1 FY27 Earnings Call for Investors

The latest announcement is out from Laurus Labs Ltd. ( ($IN:LAURUSLABS) ). Laurus Labs has notified the stock...

3M ago

Laurus Labs Concludes 21st AGM with Strong Virtual Shareholder Participation

An update from Laurus Labs Ltd. ( ($IN:LAURUSLABS) ) is now available. Laurus Labs Ltd. held its 21st...

4M ago

Laurus Labs strengthens board with new independent directors

An announcement from Laurus Labs Ltd. ( ($IN:LAURUSLABS) ) is now available. Laurus Labs Ltd., a publicly listed...

4M ago

Laurus Labs shuts trading window ahead of June-quarter results

Laurus Labs Ltd. ( ($IN:LAURUSLABS) ) has shared an update. Laurus Labs Ltd. has announced the closure of...

4M ago

Laurus Labs Closes Trading Window Ahead of FY26 Results

Laurus Labs Ltd. ( ($IN:LAURUSLABS) ) has provided an announcement. Laurus Labs Limited has announced that its trading...

7M ago

Laurus Labs Releases Q2 FY26 Results Conference Call Recording

Laurus Labs Ltd. ( ($IN:LAURUSLABS) ) has provided an announcement. Laurus Labs Ltd. announced the availability of the...

12M ago

LAURUSLABS FAQ

What was Laurus Labs Ltd.’s price range in the past 12 months?

Laurus Labs Ltd. lowest stock price was ₹901.85 and its highest was ₹2087.00 in the past 12 months.

What is Laurus Labs Ltd.’s market cap?

Laurus Labs Ltd.’s market cap is ₹1.11T.

When is Laurus Labs Ltd.’s upcoming earnings report date?

Laurus Labs Ltd.’s upcoming earnings report date is Oct 29, 2026 which is in 6 days.

How were Laurus Labs Ltd.’s earnings last quarter?

Laurus Labs Ltd. released its earnings results on Jul 24, 2026. The company reported ₹6.8 earnings per share for the quarter, beating the consensus estimate of ₹4.912 by ₹1.888.

Is Laurus Labs Ltd. overvalued?

According to Wall Street analysts Laurus Labs Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Laurus Labs Ltd. pay dividends?

Laurus Labs Ltd. pays a Semiannually dividend of ₹1.2 which represents an annual dividend yield of 0.1%. See more information on Laurus Labs Ltd. dividends here

What is Laurus Labs Ltd.’s EPS estimate?

Laurus Labs Ltd.’s EPS estimate is 6.67.

How many shares outstanding does Laurus Labs Ltd. have?

Laurus Labs Ltd. has 540,312,200 shares outstanding.

What happened to Laurus Labs Ltd.’s price movement after its last earnings report?

Laurus Labs Ltd. reported an EPS of ₹6.8 in its last earnings report, beating expectations of ₹4.912. Following the earnings report the stock price went up 2.168%.

Which hedge fund is a major shareholder of Laurus Labs Ltd.?

Currently, no hedge funds are holding shares in IN:LAURUSLABS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Laurus Labs Ltd.

Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.

Laurus Labs Ltd. (LAURUSLABS) Earnings & Revenues

Historic Earnings Reports

LAURUSLABS Stock 12 Month Forecast

Average Price Target

₹1,700.00

▲(6.10% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"869":"₹869","1990":"₹1,990","1149.25":"₹1,149.3","1429.5":"₹1,429.5","1709.75":"₹1,709.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.70K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.70K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.70K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[869,1149.25,1429.5,1709.75,1990],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1989,1966.7692307692307,1944.5384615384614,1922.3076923076924,1900.076923076923,1877.8461538461538,1855.6153846153845,1833.3846153846155,1811.1538461538462,1788.923076923077,1766.6923076923076,1744.4615384615386,1722.2307692307693,{"y":1700,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1989,1966.7692307692307,1944.5384615384614,1922.3076923076924,1900.076923076923,1877.8461538461538,1855.6153846153845,1833.3846153846155,1811.1538461538462,1788.923076923077,1766.6923076923076,1744.4615384615386,1722.2307692307693,{"y":1700,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1989,1966.7692307692307,1944.5384615384614,1922.3076923076924,1900.076923076923,1877.8461538461538,1855.6153846153845,1833.3846153846155,1811.1538461538462,1788.923076923077,1766.6923076923076,1744.4615384615386,1722.2307692307693,{"y":1700,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":870.464,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":953.55,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1027.926,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1108.995,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":952.951,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1063.89,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1038.216,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1098.006,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1388.4,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1493.6,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1816.1,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1860,"date":1788220800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1989,"date":1790812800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >